MTOR and acute myeloid leukemia: Among the results, they found that CHR2863-resistant AML cell models were able to sequester CHR2863 into LDs, with a consequent increase in LDs in cells and activation of the pro-survival Akt/mTOR pathway, which could be targeted using mTOR-targeted drugs like rapamycin to overcome CHR2863 drug resistance [28].